A preliminary algorithm introducing immunogenicity assessment in the management of patients with RA receiving tumour necrosis factor inhibitor therapies

• Published in: Annals of the rheumatic diseases Vol. 73; no. 6; pp. 1138 - 1143
• Main Authors: Garcês, Sandra, Antunes, Marília, Benito-Garcia, Elizabeth, da Silva, José Canas, Aarden, Lucien, Demengeot, Jocelyne
• Format: Journal Article
• Language: English
• Published: England Elsevier Limited 01.06.2014
• Subjects: Adalimumab; Adult; Aged; Algorithms; Antibodies - immunology; Antibodies, Monoclonal - immunology; Antibodies, Monoclonal - therapeutic use; Antibodies, Monoclonal, Humanized - immunology; Antibodies, Monoclonal, Humanized - therapeutic use; Antirheumatic Agents - immunology; Antirheumatic Agents - therapeutic use; Arthritis, Rheumatoid - drug therapy; Arthritis, Rheumatoid - immunology; Biological Products - immunology; Clinical medicine; Disease Management; Etanercept; Female; Gangrene; Humans; Immunoglobulin G - immunology; Immunoglobulin G - therapeutic use; Immunoglobulins; Infliximab; Male; Middle Aged; Receptors, Tumor Necrosis Factor - immunology; Receptors, Tumor Necrosis Factor - therapeutic use; Response rates; Rheumatology; Studies; Treatment Failure; Treatment Outcome; Tumor Necrosis Factor-alpha - antagonists & inhibitors; Tumor necrosis factor-TNF; Rheumatoid Arthritis; Anti-TNF; DMARDs (biologic)

Introduction Clinical remission is today the treatment goal for rheumatoid arthritis (RA), which requires fast and assertive therapeutic decisions for a tight control of disease activity. Few objective parameters are available to guide clinical decisions, particularly in switcher patients. We design...